Please login to the form below

SCLC

This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.

FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer

The treatment, which was approved on Friday, has claimed the title of the first and only immuno-oncology treatment for SCLC patients who have received platinum chemo and at least one ... This ‘hard-to-treat’disease accounts for up to 15% of all lung

Latest news

Pivotal data sets up Tecentriq filing in small cell lung cancer

Tecentriq (atezolizumab) as a front-line therapy in combination with chemotherapy for ES-SCLC. ... Typically, 5% or less of ES-SCLC patients – in whom the tumour has spready beyond the lung and adjacent lymph nodes – are still alive after five years.
AbbVie slumps on trial results for would-be blockbuster Rova-T

potential while moving swiftly ahead with additional trials in both second-line (TAHOE) and first-line SCLC (MERU). ... and remain committed to developing Rova-T for the treatment of patients with SCLC.".
Biotecnol taps into Cancer Research UK network for first trial

despite treatment, particularly mesothelioma, small-cell lung carcinoma (SCLC) and non-small cell lung cancer (NSCLC), and renal cell carcinoma.
AbbVie's PARP inhibitor veliparib fails to deliver

Rova-T for small cell lung cancer (SCLC) and ABT-414 for the brain cancer glioblastoma.
Unhappy times continue at OncoMed with more disappointing results

progression-free survival (PFS) or overall survival (OS) when added to chemotherapy in patients with small-cell lung cancer (SCLC) in the PINNACLE trial.

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Deal Watch February 2017

triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.
Deal Watch April 2016

Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.
Deal Watch November 2015

July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Associate Scientific Director: Salary TBC

Account Director or Senior Account Director: Salary TBC

Account Director, Healthcare Advertising Agency: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Senior Medical Writer: Salary is DOE

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Training Manager - Surrey: Competitive Salary &Bonus

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior Medical Writer, MedComms Agency: Salary TBC

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Senior Account Manager – Healthcare Advertising: Salary TBC

Systematic Review Lead- London: Negotiable

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Sudler London - Account Director: Competitive

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....